$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-K Financial Statement

#000114420415054864 Filed on September 14, 2015

Income Statement

Concept	2015 Q2	2015	2014 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.050M	$3.400M	$1.590M
YoY Change	-33.96%	-3.95%	189.09%
% of Gross Profit
Research & Development	$1.390M	$3.660M	$2.200M
YoY Change	-36.82%	-28.67%	117.82%
% of Gross Profit
Depreciation & Amortization	$140.0K	$294.2K	$50.00K
YoY Change	180.0%	44.77%	0.0%
% of Gross Profit
Operating Expenses	$2.440M	$7.063M	$3.790M
YoY Change	-35.62%	-18.51%	142.95%
Operating Profit		-$7.063M
YoY Change		-18.51%
Interest Expense	$1.830M	$2.650M	-$1.400M
YoY Change	-230.71%	-14.32%	185.71%
% of Operating Profit
Other Income/Expense, Net	-$310.0K	$4.865M	-$150.0K
YoY Change	106.67%	-198.6%	15.38%
Pretax Income	-$920.0K	-$2.198M	-$5.340M
YoY Change	-82.77%	-83.84%	144.95%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$920.0K	-$2.198M	-$5.340M
YoY Change	-82.77%	-83.84%	144.95%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.04
Diluted Earnings Per Share	-$321.7K	-$0.09	-$1.978M
COMMON SHARES
Basic Shares Outstanding	57.15M shares	56.55M shares	54.54M shares
Diluted Shares Outstanding		59.22M shares

Balance Sheet

Concept	2015 Q2	2015	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.47M	$31.47M	$36.70M
YoY Change	-14.25%	-14.26%	163.65%
Cash & Equivalents	$31.47M	$31.47M	$36.70M
Short-Term Investments
Other Short-Term Assets	$0.00	$214.4K	$150.0K
YoY Change	-100.0%	-17.53%	-75.0%
Inventory
Prepaid Expenses	$214.4K		$108.1K
Receivables
Other Receivables
Total Short-Term Assets	$31.68M	$31.68M	$36.95M
YoY Change	-14.27%	-14.26%	154.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.96M	$11.96M	$5.497M
YoY Change	117.63%	117.5%	1072.28%
Goodwill
YoY Change
Intangibles	$399.7K		$408.3K
YoY Change	-2.09%		-2.1%
Long-Term Investments
YoY Change
Other Assets	$140.0K	$142.5K	$1.000M
YoY Change	-86.0%	-85.75%	0.0%
Total Long-Term Assets	$12.50M	$12.50M	$6.905M
YoY Change	81.1%	80.97%	266.13%
TOTAL ASSETS
Total Short-Term Assets	$31.68M	$31.68M	$36.95M
Total Long-Term Assets	$12.50M	$12.50M	$6.905M
Total Assets	$44.19M	$44.19M	$43.86M
YoY Change	0.75%	0.75%	167.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$410.0K	$405.7K	$430.0K
YoY Change	-4.65%	-5.65%	-55.67%
Accrued Expenses	$28.52K	$28.52K	$91.84K
YoY Change	-68.95%	-68.31%	-55.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$600.9K	$600.9K	$517.7K
YoY Change	16.06%	15.56%	-56.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$7.181M	$5.000M
YoY Change	-100.0%	-20.56%	44.17%
Other Long-Term Liabilities	$4.620M	$4.619M	$10.94M
YoY Change	-57.77%	-57.78%	191.73%
Total Long-Term Liabilities	$11.80M	$11.80M	$19.97M
YoY Change	-40.92%	-40.94%	176.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$600.9K	$600.9K	$517.7K
Total Long-Term Liabilities	$11.80M	$11.80M	$19.97M
Total Liabilities	$12.40M	$12.40M	$20.49M
YoY Change	-39.48%	-39.48%	144.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.10M		-$51.90M
YoY Change	4.24%
Common Stock	$57.24K		$54.62K
YoY Change	4.8%		16.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.79M	$31.79M	$23.37M
YoY Change
Total Liabilities & Shareholders Equity	$44.19M	$44.19M	$43.86M
YoY Change	0.75%	0.75%	167.32%

Cashflow Statement

Concept	2015 Q2	2015	2014 Q2
OPERATING ACTIVITIES
Net Income	-$920.0K	-$2.198M	-$5.340M
YoY Change	-82.77%	-83.84%	144.95%
Depreciation, Depletion And Amortization	$140.0K	$294.2K	$50.00K
YoY Change	180.0%	44.77%	0.0%
Cash From Operating Activities	-$1.250M	-$6.212M	-$950.0K
YoY Change	31.58%	-1.86%	-30.66%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	$6.760M	-$1.610M
YoY Change	-25.47%	29.23%	2583.33%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.000M	$1.000M
YoY Change	-100.0%
Cash From Investing Activities	-$1.200M	-$5.760M	-$610.0K
YoY Change	96.72%	10.14%	916.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	6.743M	5.000M
YoY Change	-100.0%	-80.36%	-5100.0%
NET CHANGE
Cash From Operating Activities	-1.250M	-6.212M	-950.0K
Cash From Investing Activities	-1.200M	-5.760M	-610.0K
Cash From Financing Activities	0.000	6.743M	5.000M
Net Change In Cash	-2.450M	-5.229M	3.440M
YoY Change	-171.22%	-122.95%	-324.84%
FREE CASH FLOW
Cash From Operating Activities	-$1.250M	-$6.212M	-$950.0K
Capital Expenditures	-$1.200M	$6.760M	-$1.610M
Free Cash Flow	-$50.00K	-$12.97M	$660.0K
YoY Change	-107.58%	12.21%	-150.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	408258	USD
CY2015Q2	us-gaap	Assets Assets	44187089	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	600895	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	517739	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	57242	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	54621	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85824613	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75212888	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54099572	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51901400	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	31785867	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	23369303	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44187089	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43859995	USD
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2014Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5000000	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11800327	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19972953	USD
CY2015Q2	us-gaap	Liabilities Liabilities	12401222	USD
CY2014Q2	us-gaap	Liabilities Liabilities	20490692	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	91838	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	49455	USD
CY2015Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	316196	USD
CY2014Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	376446	USD
CY2015Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	89517	USD
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q4	dei	Entity Public Float EntityPublicFloat	112046000	USD
CY2015	dei	Trading Symbol TradingSymbol	NNVC
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57240000	shares
CY2014Q2	us-gaap	Assets Assets	43859995	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3402778	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	8667372	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	7063100	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	399737	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	50696	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	59217	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5496756	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11962648	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1239986	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1534203	USD
CY2014Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6736742	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13496851	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	36954981	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	31682173	USD
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	108089	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	214425	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36696892	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	0	USD
CY2014Q2	us-gaap	Security Deposit SecurityDeposit	1000000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	0	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	150000	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2014Q2	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	6590379	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-8667372	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-7063100	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-6590379	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	171001	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	160859	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	55587	USD
CY2014	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	569495	USD
CY2015	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	1175344	USD
CY2013	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	129006	USD
CY2014	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1443200	USD
CY2015	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8529005	USD
CY2013	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1249335	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4934244	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4864928	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2285289	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13601616	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2198172	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5131523	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3660322	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4292909	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8875668	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-13601616	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-2198172	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-8875668	USD
CY2014	us-gaap	Interest Expense InterestExpense	3092550	USD
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56553848	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45892549	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51225622	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59220515	shares
CY2014	us-gaap	Interest Paid InterestPaid	480000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13601616	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5276036	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015	us-gaap	Interest Expense InterestExpense	2649592	USD
CY2013	us-gaap	Interest Expense InterestExpense	962535	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51225622	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47606835	shares
CY2015	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	877234	USD
CY2014	nnvc	Shares And Warrants Issued For Services SharesAndWarrantsIssuedForServices	434861	USD
CY2015	nnvc	Shares And Warrants Issued For Services SharesAndWarrantsIssuedForServices	279363	USD
CY2014	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-2605716	USD
CY2015	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-1502870	USD
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2014	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	199849	USD
CY2015	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	59675	USD
CY2014	us-gaap	Depreciation Depreciation	203234	USD
CY2015	us-gaap	Depreciation Depreciation	294217	USD
CY2014	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8775	USD
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8521	USD
CY2014	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-1443200	USD
CY2015	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	8529005	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	56492	USD
CY2015	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	106336	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	113188	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-286930	USD
CY2014	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-112521	USD
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-63323	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6333625	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6212332	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5231094	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6760109	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5231094	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5760109	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	28602740	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	735626	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6743297	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	34338366	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6743297	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22773647	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5229144	USD
CY2015	us-gaap	Interest Paid InterestPaid	480000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2014	nnvc	Discount On Longterm Convertible Debentures DiscountOnLongtermConvertibleDebentures	569495	USD
CY2015	nnvc	Discount On Longterm Convertible Debentures DiscountOnLongtermConvertibleDebentures	1175344	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1152297	USD
CY2014	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD
CY2015	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	1879428	USD
CY2014	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	0	USD
CY2015	nnvc	Issuance Of Series C Debenture For Deposit Received IssuanceOfSeriesCDebentureForDepositReceived	5000000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6512390	shares
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8875668	USD
CY2015	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2014	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.27
CY2015	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2014	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.27
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13601616	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2198172	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9210500	USD
CY2013	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-334832	USD
CY2014	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-3077864	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1714286	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2666667	shares
CY2015Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2014Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	4000000	USD
CY2015Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7905938	USD
CY2014Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3099780	USD
CY2015Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	65241	USD
CY2014Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	30048	USD
CY2015Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2014Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1400	USD
CY2015Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5264272	USD
CY2014Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	3605514	USD
	us-gaap	Depreciation Depreciation	203234	USD
CY2014Q4	nnvc	Closing Costs Of Facility ClosingCostsOfFacility	81230	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	68592	shares
CY2015Q2	nnvc	Fair Value Of Common Stock Warrant Issued During Period For Consulting Services FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices	59675	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	104340	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	104340	USD
CY2011Q1	nnvc	Space For Office And Laboratory SpaceForOfficeAndLaboratory	7000	sqft
CY2011Q1	nnvc	Monthly Base Rent MonthlyBaseRent	8695	USD
CY2015	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 1  Organization and Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Colorado</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Edot-com.com, Inc.</font> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc<b>.,</b> the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"> Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35</font></font> million shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis</font>, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECCM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), an entity owned and controlled by a significant stockholder, to which we have the necessary exclusive, worldwide licenses in perpetuity. The first agreement we executed with TheraCour Pharma on  September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive, worldwide licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.</font> The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the holder’s approval. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Other Assets OtherAssets	142531	USD
CY2014Q2	us-gaap	Other Assets OtherAssets	1000000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	85714286	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57242070	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57242070	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54620993	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54620993	shares
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	445044	USD
CY2013	nnvc	Shares And Warrants Issued For Services SharesAndWarrantsIssuedForServices	163710	USD
CY2013	nnvc	Common Shares Issued For Interest CommonSharesIssuedForInterest	-665497	USD
CY2013	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	141600	USD
CY2013	us-gaap	Depreciation Depreciation	210877	USD
CY2013	us-gaap	Adjustment For Amortization AdjustmentForAmortization	8774	USD
CY2013	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-1249335	USD
CY2013	nnvc	Discount On Longterm Convertible Debentures DiscountOnLongtermConvertibleDebentures	0	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	284206	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	24900	USD
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u><font style="FONT-SIZE: 10pt">Concentrations of Risk</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
CY2015	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-266741	USD
CY2014	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	114329	USD
CY2013	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-344886	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	107479	USD
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-500000	USD
CY2014	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2013	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	142531	USD
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-150000	USD
CY2014	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	150000	USD
CY2013	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5797772	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64931	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1064931	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6000000	USD
CY2013	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	510963	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6510963	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-351740	USD
CY2013	us-gaap	Interest Paid InterestPaid	197589	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013	nnvc	Bifurccation Of Embedded Derivative BifurccationOfEmbeddedDerivative	0	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	nnvc	Common Stock Issued Upon Conversion Of Series B Preferred Stock CommonStockIssuedUponConversionOfSeriesBPreferredStock	0	USD
CY2014	nnvc	Common Stock Issued Upon Conversion Of Series B Preferred Stock CommonStockIssuedUponConversionOfSeriesBPreferredStock	0	USD
CY2013	nnvc	Common Stock Issued Upon Conversion Of Series B Preferred Stock CommonStockIssuedUponConversionOfSeriesBPreferredStock	3028464	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13923245	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14274985	USD
CY2015	us-gaap	Operating Loss Carryforwards Expiration Date OperatingLossCarryforwardsExpirationDate	2035-06-30
CY2015	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
CY2015	nnvc	Lab Supplies And Chemicals Fees LabSuppliesAndChemicalsFees	25000	USD
CY2015	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2014Q2	us-gaap	Land Land	0	USD
CY2015Q2	us-gaap	Land Land	260000	USD
CY2010Q1	nnvc	Minimum Annual Base Salary MinimumAnnualBaseSalary	250000	USD
CY2010Q1	nnvc	Proceeds From Financing ProceedsFromFinancing	5000000	USD
CY2010Q1	nnvc	Employment Agreement Term EmploymentAgreementTerm	P4Y
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3744	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4584	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0120	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0167	pure
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	nnvc	Purchase Price Per Unit Description PurchasePricePerUnitDescription	The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Companys stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Companys stock on Friday, January 17, 2014. Each Unit consisted of one share of the Companys common stock, par value $0.001 per share (the Common Stock) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (Warrant),
CY2013Q3	nnvc	Description Of Offering DescriptionOfOffering	the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share.
CY2014Q1	nnvc	Description Of Offering DescriptionOfOffering	the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share.
CY2013Q4	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	7143	shares
CY2013Q4	nnvc	Stock Issued During Period Price Per Share One StockIssuedDuringPeriodPricePerShareOne	3.50
CY2014Q1	nnvc	Stock Issued During Period Price Per Share One StockIssuedDuringPeriodPricePerShareOne	5.25
CY2014Q1	nnvc	Warrants Exercise Price WarrantsExercisePrice	6.05
CY2015Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	20030207	USD
CY2015Q1	nnvc	Placement Agents And Attorneys Fees PlacementAgentsAndAttorneysFees	1200000	USD
CY2013Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	113696	USD
CY2013Q3	nnvc	Purchase Price Per Share PurchasePricePerShare	3.50
CY2013Q3	nnvc	Stock Issued During Period Price Per Share StockIssuedDuringPeriodPricePerShare	5.25
CY2013Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	10308996	USD
CY2013Q3	nnvc	Placement Agents And Attorneys Fees PlacementAgentsAndAttorneysFees	618540	USD
CY2013Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2945428	shares
CY2014Q1	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	75000	shares
CY2014Q1	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	25000	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	393750	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	131750	USD
CY2013	nnvc	Number Of Common Stock To Be Issued Upon Conversion Of Warrants NumberOfCommonStockToBeIssuedUponConversionOfWarrants	71428	shares
CY2013	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	445044	USD
CY2013	nnvc	Series C Preferred Shares Issued During Period Value Issued SeriesCPreferredSharesIssuedDuringPeriodValueIssued	2541872	USD
CY2013	nnvc	Common Stock Issued During Period Retirement Of Series C Preferred Shares Value CommonStockIssuedDuringPeriodRetirementOfSeriesCPreferredSharesValue	1	USD
CY2013	nnvc	Common Stock Issued During Period Conversion Of Series C Preferred Shares Value CommonStockIssuedDuringPeriodConversionOfSeriesCPreferredSharesValue	6352	USD
CY2013	nnvc	Common Stock Issue For Dividend Value Issued CommonStockIssueForDividendValueIssued	90108	USD
CY2013	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	84956	USD
CY2013	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	141600	USD
CY2013	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	60000	USD
CY2013	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	665497	USD
CY2013	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	18750	USD
CY2013	nnvc	Adjustments To Additional Paid In Capital Dividends Paid AdjustmentsToAdditionalPaidInCapitalDividendsPaid	96110	USD
CY2013	nnvc	Adjustment To Additional Paid In Capital Derivative Liability Retirement Of Series C Preferred Shares Issued For June AdjustmentToAdditionalPaidInCapitalDerivativeLiabilityRetirementOfSeriesCPreferredSharesIssuedForJune	968894	USD
CY2013	nnvc	Adjustments To Additional Paid In Capital Placement Agents Fee Conversion AdjustmentsToAdditionalPaidInCapitalPlacementAgentsFeeConversion	165000	USD
CY2013	nnvc	Adjustments To Additional Paid In Capital Legal Fee Conversion AdjustmentsToAdditionalPaidInCapitalLegalFeeConversion	12500	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	8009652	USD
CY2013	nnvc	Stock Issued During Period Redemption Of Series C Convertible Preferred Stok Value StockIssuedDuringPeriodRedemptionOfSeriesCConvertiblePreferredStokValue	1714334	USD
CY2014	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	2123014	USD
CY2014	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	102001	USD
CY2014	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	199849	USD
CY2014	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	287860	USD
CY2014	nnvc	Common Shares Issued In Connection With Warrant Conversion CommonSharesIssuedInConnectionWithWarrantConversion	735624	USD
CY2014	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	2605716	USD
CY2014	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2014	nnvc	Common Shares And Warrants Issued Value In Connection With Private Placement Of Common Stock CommonSharesAndWarrantsIssuedValueInConnectionWithPrivatePlacementOfCommonStock	30339203	USD
CY2014	nnvc	Common Shares Issues Value To Round Up Financial Shares Arising From Private Placement CommonSharesIssuesValueToRoundUpFinancialSharesArisingFromPrivatePlacement	0	USD
CY2014	nnvc	Placement Agents Fees Related To Sale Of Common Shares And Warrants PlacementAgentsFeesRelatedToSaleOfCommonSharesAndWarrants	1820360	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	83900	USD
CY2014	nnvc	Restatement Of Additional Paid In Capital To Derivative Liability RestatementOfAdditionalPaidInCapitalToDerivativeLiability	5740540	USD
CY2015	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	852760	USD
CY2015	nnvc	Series Preferred Shares Value Issued For Consulting And Legal Services Rendered SeriesPreferredSharesValueIssuedForConsultingAndLegalServicesRendered	24474	USD
CY2015	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	45000	USD
CY2015	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	109360	USD
CY2015	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	59675	USD
CY2015	nnvc	Common Stock Issued During Period Employee Stock Compensation Value Issued CommonStockIssuedDuringPeriodEmployeeStockCompensationValueIssued	125003	USD
CY2015	nnvc	Common Shares Issued In Connection With Warrant Conversion CommonSharesIssuedInConnectionWithWarrantConversion	6743297	USD
CY2015	nnvc	Common Stock Shares Issued For Payment Of Debenture Interest Value CommonStockSharesIssuedForPaymentOfDebentureInterestValue	1502870	USD
CY2015	nnvc	Series Preferred Shares Issued For Debenture Interest SeriesPreferredSharesIssuedForDebentureInterest	1152297	USD
CY2015	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	-1000000	USD
CY2014	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	0	USD
CY2014Q2	nnvc	Service Agreements ServiceAgreements	0	USD
CY2015	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
CY2015	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	13850192	USD
CY2015Q2	nnvc	Service Agreements ServiceAgreements	142531	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
CY2015	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
CY2014Q4	nnvc	Acquisition And Renovation Expenses Of Manufacturing And Lab Facility AcquisitionAndRenovationExpensesOfManufacturingAndLabFacility	4222549	USD
CY2011Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2011-02-28
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	102030	USD
CY2013	nnvc	Common Stock Issued During Period Settlement Of Accounts Payable Value CommonStockIssuedDuringPeriodSettlementOfAccountsPayableValue	60000	USD
CY2015	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.5	pure
CY2013Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 3.5
CY2013Q3	nnvc	Fair Value Of Common Stock Warrant Issued During Period For Consulting Services FairValueOfCommonStockWarrantIssuedDuringPeriodForConsultingServices	113696	USD
CY2013	nnvc	Stock Issued During Period Price Per Share One StockIssuedDuringPeriodPricePerShareOne	0.001
CY2014Q3	nnvc	Warrants Issued To Purchase Of Common Stock WarrantsIssuedToPurchaseOfCommonStock	1926656	shares
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.50
CY2014Q3	nnvc	Aggregate Purchase Price Of Warrants AggregatePurchasePriceOfWarrants	6743297	USD
CY2015	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	i) the converted value to common at a ratio of 1:3.5
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	399737	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	408258	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8521	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8521	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8521	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8521	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8521	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	357132	USD
CY2013	us-gaap	Payments For Advance To Affiliate PaymentsForAdvanceToAffiliate	1000000	USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	333333	USD
CY2014Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	0	USD
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2910071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2379935	shares
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	nnvc	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.05
CY2015	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Reclassifications</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3400	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	-0.3400	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.3700	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.3700	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.7100	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.7100	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5400000	USD
CY2015Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	43400000	USD
CY2015Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16394801	USD
CY2014Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13408064	USD
CY2015Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4800186	USD
CY2014Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3422745	USD
CY2015Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5214064	USD
CY2014Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4178211	USD
CY2015Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26409051	USD
CY2014Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21009020	USD
CY2015Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26409051	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21009020	USD
CY2015Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD

Files In Submission

Name	View Source	Status
0001144204-15-054864-index-headers.html	Edgar Link	pending
0001144204-15-054864-index.html	Edgar Link	pending
0001144204-15-054864.txt	Edgar Link	pending
0001144204-15-054864-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20150630.xml	Edgar Link	completed
nnvc-20150630.xsd	Edgar Link	pending
nnvc-20150630_cal.xml	Edgar Link	unprocessable
nnvc-20150630_def.xml	Edgar Link	unprocessable
nnvc-20150630_lab.xml	Edgar Link	unprocessable
nnvc-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsig.jpg	Edgar Link	pending
v418491_10k.htm	Edgar Link	pending
v418491_ex31-1.htm	Edgar Link	pending
v418491_ex31-2.htm	Edgar Link	pending
v418491_ex32-1.htm	Edgar Link	pending
v418491_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2015 Q2 Form 10-K Financial Statement

#000114420415054864 Filed on September 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2015 Q2 Form 10-K Financial Statement

#000114420415054864 Filed on September 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc